Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=other_investigators" }, "data": [ { "type": "Grant", "id": "7359", "attributes": { "award_id": "3R01DK112322-05S1", "title": "Dulce Digital-COVID Aware (DD-CA) discharge texting platform for US/Mexico border Hispanics with diabetes + COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6099, "first_name": "SHAVON", "last_name": "Artis Dickerson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2016-09-20", "end_date": "2022-08-31", "award_amount": 306364, "principal_investigator": { "id": 23156, "first_name": "Adelaide L", "last_name": "Fortmann", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1572, "ror": "https://ror.org/05bhsww40", "name": "Scripps Health", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23157, "first_name": "Athena", "last_name": "Philis-Tsimikas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1572, "ror": "https://ror.org/05bhsww40", "name": "Scripps Health", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Hispanics, a group that shows higher type 2 diabetes (T2D) prevalence, and poor self-management and clinical outcomes, have been disproportionally adversely impacted by COVID-19. The California Department of Public Health reports that Hispanics make up 39% of California’s population but an unprecedented 57% of the confirmed COVID-19 cases. This devastating finding is especially notable on the US/Mexico border. Diabetes has emerged as a leading risk factor for severe COVID-19 illness leading to hospitalization, is associated with greater disease severity and mortality and is an independent predictor of intensive care placement and invasive ventilation. It is becoming increasingly clear that maintaining good glucose control improves prognosis of COVID-19 among people with pre-existing T2D. However, social distancing, quarantine, and stay-at- home/lockdown guidelines may impact one’s ability to maintain adequate glycemic control. Research is needed to evaluate the effect and clinical outcomes of a flexible, easily adopted low cost digital intervention that improves glucose excursions and provides urgently needed COVID-19 mitigation strategies, among rapidly rising groups of high-risk Hispanics with poorly controlled T2D in US/Mexico border communities. Strong evidence from our parent grant Dulce Digital-Me, supports the use of technology (such as text messaging) alone or in combination with coaching interventions as a viable and desired method of delivering tailored diabetes self-management education and COVID awareness messaging to high-risk, underserved populations in a manner that is more convenient for both patients and staff while having the added benefit of being cost-effective for health systems, especially within low resource settings. However, effective interventions may encounter barriers which preclude guaranteed success upon implementation in the real world. This project, taking place along the San Diego/Tijuana border, historically the busiest land port of entry in the Western Hemisphere, will assess the effect of providing an enhanced digital texting intervention-Dulce Digital-COVID Aware (DD-CA) to N = 172 Hispanic patients with T2D upon discharge from a recent hospitalization. Key outcomes will assess the impact of DD-CA on hospital readmissions at 30 and 90 days post-discharge, glucose control and patient reported outcomes at 90 days post-discharge while also assessing COVID status and the implementation process. Given that DD-CA offers the potential to address many of the practical barriers to access and extend the reach of diabetes services, while additionally providing COVID awareness support, it offers an ideal low-cost and flexible solution to reduce hospital admissions and re- admissions in US/Mexico border communities significantly and simultaneously affected by COVID-19 and T2D. Implemented in a typical hospital and post-discharge setting, it augments existing care team processes, thus providing a valuable test of real-world effectiveness. More importantly, by helping to reduce existing inequities in access to diabetes and COVID-19 care, this program aims to improve health outcomes on a larger scale.", "keywords": [ "Address", "Adopted", "Adoption", "Adult", "Affect", "Attitude", "Awareness", "Behavior", "Behavioral", "Blood Glucose", "COVID-19", "COVID-19 pandemic", "California", "Car Phone", "Caring", "Clinical", "Communities", "Diabetes Mellitus", "Distress", "Eating", "Education", "Effectiveness", "Elderly", "Exercise", "Federally Qualified Health Center", "Feedback", "Glucose", "Glycosylated hemoglobin A", "Grant", "Guidelines", "Health", "Health Technology", "Health system", "Hispanics", "Home environment", "Hospitalization", "Hospitals", "Individual", "Infection", "Intensive Care", "Intervention", "Knowledge", "Language", "Latino", "Linguistics", "Low income", "Medical", "Methods", "Mexico", "Modeling", "Motivation", "Non-Insulin-Dependent Diabetes Mellitus", "Not Hispanic or Latino", "Outcome", "Parents", "Participant", "Patient Outcomes Assessments", "Patients", "Pharmaceutical Preparations", "Population", "Prevalence", "Process", "Public Health", "Publishing", "Quarantine", "Reporting", "Research", "Resources", "Risk Factors", "Self Management", "Services", "Severity of illness", "Social Distance", "Team Process", "Technology", "Telemedicine", "Testing", "Text Messaging", "Time", "Underserved Population", "Visit", "arm", "blood glucose regulation", "coronavirus disease", "cost", "cost effective", "design", "diabetes self-management", "digital", "effective intervention", "experience", "flexibility", "glycemic control", "health disparity", "high risk", "high risk population", "hospital readmission", "hospitalization rates", "improved", "mHealth", "medication compliance", "mortality", "novel coronavirus", "outcome forecast", "parent grant", "preference", "prevent", "programs", "randomized controlled study", "readmission rates", "success", "therapy design", "tool", "transmission process", "treatment as usual", "ventilation", "virtual" ], "approved": true } }, { "type": "Grant", "id": "7370", "attributes": { "award_id": "3R34DA050283-01S2", "title": "6/7: Longitudinal evaluation of the impact of the COVID-19 pandemic on high-risk new and expectant mothers", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 10219, "first_name": "Vani", "last_name": "Pariyadath", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-09-30", "end_date": "2021-03-31", "award_amount": 152961, "principal_investigator": { "id": 23164, "first_name": "Leigh-Anne", "last_name": "Cioffredi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1131, "ror": "", "name": "UNIVERSITY OF VERMONT & ST AGRIC COLLEGE", "address": "", "city": "", "state": "VT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23165, "first_name": "ALEXANDRA S", "last_name": "POTTER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1131, "ror": "", "name": "UNIVERSITY OF VERMONT & ST AGRIC COLLEGE", "address": "", "city": "", "state": "VT", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic represents the most significant environmental event in living history and is leading to unprecedented social, economic and health consequences. There is an urgent need to longitudinally study the impact of the pandemic on pregnant women and the care they receive, and to understand the consequences for their children’s birth outcomes and neurobehavioral development. Importantly, women with pre-existing substance use, mental health conditions and limited economic resources may be at increased risk for the wide- ranging, deleterious sequelae of the pandemic. The proposed project seeks to address these critical gaps by building upon ongoing harmonized research efforts across seven geographically-representative sites from the NIH HEALthy Brains and Cognitive Development study (HBCD) initiative, including New York University, Oregon Health Sciences University, Washington University in St. Louis, University of Pittsburgh, Cedars Sinai Medical Center, University of Vermont and Northwestern University. We will enroll pregnant and postpartum women into a multi-wave study in which we assess medical, economic, psychosocial and substance use risk across pregnancy and the perinatal period, studying associations of these factors to infant neurobehavioral development during the first year of life. Our central hypotheses include: 1) individual variation in perinatal COVID-19 related stress leads to differences in birth outcomes, parenting stress and infant temperament and neurodevelopment and 2) substance use, mental health and economic risk enhance susceptibility to negative COVID-19 related health and psychosocial outcomes. To pursue these aims, prospective longitudinal survey, birth and postpartum data will be obtained across a 3-month period in N=100 pregnant and new mothers per site (providing a total consortium sample of N=700) to generate individual temporal profiles of COVID-19 related experiences and responses, comparing outcomes with existing data from maternal-infant cohorts obtained prior to the pandemic. Further, to identify avenues for intervention, will evaluate substance use, poor mental health and low socioeconomic status as risk factors and coping, agency and utilization of resources as resilience factors that influence COVID-19 related maternal stress and child health and neurobehavioral outcomes. The effects of geographic location will be used to examine the influence of pandemic severity, variation in local government policies and resource availability on these outcomes. Finally, we will collect and bank longitudinal perinatal biospecimens in N=40 women per site that will provide a foundation for future studies to evaluate the biological mechanisms through which the effects on maternal psychological and physical health influence offspring brain and behavioral development. Through this analysis of COVID-19 related stress, contextual factors and child outcomes, we will develop a comprehensive understanding of effects and modifiers of this event on health outcomes in individuals that vary in dispositional risk during perinatal life, one of the most sensitive timepoints in human development.", "keywords": [ "Address", "Alcohol or Other Drugs use", "Apgar Score", "Behavioral", "Biological", "Biological Specimen Banks", "Biology", "Birth", "Birth Records", "Brain", "COVID-19", "COVID-19 pandemic", "Caring", "Child", "Child Health", "Child Rearing", "Childhood", "Cognitive", "Collection", "Communities", "Coping Behavior", "Data", "Data Set", "Development", "Developmental Delay Disorders", "Economics", "Emotional", "Enrollment", "Equation", "Event", "Exposure to", "Factor Analysis", "Foundations", "Future", "Gene Expression", "Geographic Locations", "Geography", "Gestational Age", "Health", "Health Sciences", "Healthcare", "Human", "Human Development", "Impact evaluation", "Individual", "Infant", "Institution", "Intervention", "Life", "Local Government", "Longitudinal Studies", "Longitudinal Surveys", "Longitudinal prospective study", "Low Birth Weight Infant", "Medical Economics", "Medical center", "Mental Health", "Modeling", "Mothers", "New York", "Oregon", "Outcome", "Parents", "Perinatal", "Policies", "Postpartum Period", "Postpartum Women", "Predisposition", "Pregnancy", "Pregnant Women", "Protocols documentation", "Proxy", "Psychological Stress", "Recording of previous events", "Research", "Resources", "Risk", "Risk Factors", "Sampling", "Severities", "Site", "Social support", "Specimen", "Stress", "Structure", "Surveys", "Testing", "Time", "Uncertainty", "United States National Institutes of Health", "Universities", "Variant", "Vermont", "Viral", "Virus", "Vulnerable Populations", "Washington", "Woman", "Work", "behavioral health", "brain health", "cognitive development", "cohort", "contextual factors", "coping", "coronavirus disease", "experience", "health economics", "high risk", "improved", "indexing", "individual variation", "infant temperament", "inflammatory marker", "interest", "low socioeconomic status", "maternal stress", "maternal weight", "microbiome", "neurobehavioral", "neurodevelopment", "offspring", "pandemic disease", "perinatal period", "physical conditioning", "postnatal", "pregnant", "prenatal", "prospective", "protective factors", "psychosocial", "public health emergency", "resilience", "response", "secondary analysis", "social", "stressor" ], "approved": true } }, { "type": "Grant", "id": "7374", "attributes": { "award_id": "3U42OD011140-18S1", "title": "National Swine Resource and Research Center 1", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 20741, "first_name": "MIGUEL A.", "last_name": "CONTRERAS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2003-09-01", "end_date": "2023-07-31", "award_amount": 499943, "principal_investigator": { "id": 23167, "first_name": "RANDALL S", "last_name": "PRATHER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1049, "ror": "", "name": "UNIVERSITY OF MISSOURI-COLUMBIA", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23168, "first_name": "Kevin Dale", "last_name": "Wells", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1049, "ror": "", "name": "UNIVERSITY OF MISSOURI-COLUMBIA", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "(Overall) The overall goal of this application is to continue and expand operation of the National Swine Resource and Research Center (NSRRC). The NSRRC is in its 14th year of operation and it has developed the infrastructure needed to assist swine-based research across multiple disciplines, including xenotransplantation. The NSRRC has developed new models of human disease by genetic engineering, it has recruited models created by others, and it has distributed expertise, cells, tissues, organs and pigs to investigators throughout the United States. Since genetic engineering of pigs requires specialized facilities and expertise, the NSRRC provides invaluable services to the research community by using the latest in gene editing technology to create new genetically-engineered swine models. The NSRRC also provides training and education by interacting with individuals, publishing manuscripts and sponsoring workshops and meetings that promote the use of pigs for studying human diseases. The NSRRC has a state-of-the-art building with high biosecurity to house animals free of specific pathogens. The Specific Aims for the upcoming grant period are as follows: 1. To operate the National Swine Research and Resource Center. Functions of the NSRRC will continue to include: a) importation of existing swine models of human health and disease; b) rederivation of pigs to eliminate specific pathogens, and health monitoring to assure maintenance of a specific pathogen-free status; c) cryopreservation and storage of gametes, embryos, and somatic cells to prevent future loss of valuable models; d) distribution of expertise, reagents, cells, tissues, organs, and pathogen-free pigs; and e) use state of the art technology for the creation of new genetically-engineered pigs needed by the biomedical research community. Rigorous quality control will ensure that only high quality genetics are distributed. The NSRRC will also serve as a site for training and educational activities related to research employing swine models. 2. To perform innovative research that will benefit the NSRRC and the biomedical research community. Applied research projects are aimed at improving: a) the cryopreservation of pig reproductive cells and tissues, b) methods for the production of genetically-engineered pigs, c) state-of-the-art testing methods for swine health surveillance, and d) right-size the pig for greater adoption of pig models.", "keywords": [ "Adoption", "Anatomy", "Animals", "Applied Research", "Area", "Arteriosclerosis", "Biomedical Research", "Cardiovascular Diseases", "Cells", "Characteristics", "Communicable Diseases", "Communities", "Country", "Critical Pathways", "Cryopreservation", "Diabetes Mellitus", "Discipline", "Disease", "Educational Activities", "Educational workshop", "Embryo", "Ensure", "Family suidae", "Future", "Genes", "Genetic", "Genetic Diseases", "Genetic Engineering", "Genetic Materials", "Germ Cells", "Goals", "Grant", "Health", "Human", "Individual", "Infrastructure", "Laboratories", "Maintenance", "Manuscripts", "Medical Device", "Medical Research", "Methods", "Modeling", "Modification", "Molecular", "Monitor", "Optics", "Organ", "Patients", "Pharmaceutical Preparations", "Physiological", "Physiology", "Play", "Production", "Progress Reports", "Publishing", "Quality Control", "Reagent", "Reproducibility", "Research", "Research Personnel", "Research Project Grants", "Resources", "Role", "Scientist", "Serologic tests", "Services", "Site", "Somatic Cell", "Study models", "Technology", "Testing", "Therapeutic", "Therapeutic Agents", "Tissues", "Training Activity", "Training and Education", "Translational Research", "United States", "United States National Institutes of Health", "Xenograft procedure", "animal care", "base", "biosecurity", "clinical practice", "drug development", "embryo cell", "experience", "germ free condition", "human disease", "human model", "improved", "innovation", "investigator training", "meetings", "novel therapeutic intervention", "novel therapeutics", "operation", "pathogen", "pig genome", "pre-clinical", "predictive modeling", "prevent", "recruit", "repository", "rho", "sperm cell", "tool" ], "approved": true } }, { "type": "Grant", "id": "7376", "attributes": { "award_id": "3U19AI090023-11S1", "title": "System Biological Analyses of Innate and Adaptive Responses to Vaccination", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6484, "first_name": "Gang", "last_name": "Dong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-07-13", "end_date": "2022-06-30", "award_amount": 7425306, "principal_investigator": { "id": 6019, "first_name": "Rafi", "last_name": "Ahmed", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 7241, "first_name": "BALI", "last_name": "PULENDRAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 23170, "first_name": "Shuzhao", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23171, "first_name": "Nadine Georges", "last_name": "Rouphael", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23172, "first_name": "Shankar", "last_name": "Subramaniam", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23173, "first_name": "Nir", "last_name": "Yosef", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23174, "first_name": "Tianwei", "last_name": "Yu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) pandemic poses a major global health challenge. Coronavirus disease (COVID-19) is caused by SARS- CoV-2 and represents the causative agent of a potentially fatal disease. Science has moved very rapidly in isolating, sequencing, and cloning the virus, and developing diagnostic kits, within a matter of weeks. However, major knowledge gaps remain about the dynamic interaction between the human immune system and the SARS-CoV-2. In particular, several fundamental questions regarding its pathogenesis, and the mechanisms of protective immunity that need to be induced by vaccination, remain unanswered. Learning how the immune system senses SARS-CoV-2 infection and orchestrates protective immunity is critical for designing effective vaccines and therapeutics. Our previous work using systems biology, multi-omics approaches to analyze immune responses to vaccination in humans has delineated molecular signatures of innate immunity to vaccination and infection and have provided rich mechanistic insights into the immune response1-7. In this proposal, we propose a site-specific study to analyze samples from the IMPACC sub-study performed at Emory. We will use an integrated multi-omics approach (single cell transcriptomics, metabolomics, single cell epigenomics) to study innate immunity to COVID- 19 infection in humans. We will obtain PBMCs and tracheal aspirate samples from the IMPACC sub-study that will be conducted at Emory. We will address the following questions: What are the molecular and cellular signatures of the immune response to COVID-19 infection in the blood and tracheal aspirates of infected subjects? Does COVID-19 infection exert an epigenetic imprint of innate immunity? What is the molecular landscape and function of myeloid cell subsets and airway epithelial cells in the healthy lung, and following COVID-19 infection? These questions will be addressed in the following specific aims: 1) Determine the single cell transcriptional and epigenetic landscape of the immune response to COVID-19 infection in blood and tracheal aspirates, and 2) Determine the molecular identity and functions of myeloid cell subsets and epithelial cells in human lung and their response to COVID-19 infection. These studies will provide significant insight into the human immune response to COVID-19 infection that can be leveraged for designing vaccines and therapeutics to prevent or treat the infection.", "keywords": [ "2019-nCoV", "ATAC-seq", "Address", "Aspirate substance", "Award", "Blood", "COVID-19", "Cell Culture Techniques", "Cells", "Cloning", "Competence", "Diagnostic", "Disease", "Donor person", "Epigenetic Process", "Epithelial Cells", "Epitopes", "Genetic Transcription", "Grant", "Heterogeneity", "Hospitals", "Human", "Immune", "Immune response", "Immune system", "Immunity", "Immunology", "Infection", "Innate Immune Response", "Knowledge", "Learning", "Lung", "Lung Transplantation", "Metabolic", "Molecular", "Molecular Profiling", "Myelogenous", "Myeloid Cells", "Natural Immunity", "Parents", "Pathogenesis", "Pathogenicity", "Peripheral Blood Mononuclear Cell", "Sampling", "Science", "Site", "Stimulus", "Structure of parenchyma of lung", "System", "Systems Biology", "Therapeutic", "Vaccination", "Vaccine Design", "Vaccines", "Virus", "Work", "airway epithelium", "biological systems", "coronavirus disease", "design", "epigenomics", "global health", "imprint", "indexing", "insight", "macrophage", "metabolomics", "monocyte", "multiple omics", "novel", "pandemic disease", "prevent", "programs", "response", "single-cell RNA sequencing", "transcriptome", "transcriptomics", "transplant centers" ], "approved": true } }, { "type": "Grant", "id": "7376", "attributes": { "award_id": "3U19AI090023-11S1", "title": "System Biological Analyses of Innate and Adaptive Responses to Vaccination", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6484, "first_name": "Gang", "last_name": "Dong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-07-13", "end_date": "2022-06-30", "award_amount": 7425306, "principal_investigator": { "id": 6019, "first_name": "Rafi", "last_name": "Ahmed", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 7241, "first_name": "BALI", "last_name": "PULENDRAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 23170, "first_name": "Shuzhao", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23171, "first_name": "Nadine Georges", "last_name": "Rouphael", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23172, "first_name": "Shankar", "last_name": "Subramaniam", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23173, "first_name": "Nir", "last_name": "Yosef", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23174, "first_name": "Tianwei", "last_name": "Yu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) pandemic poses a major global health challenge. Coronavirus disease (COVID-19) is caused by SARS- CoV-2 and represents the causative agent of a potentially fatal disease. Science has moved very rapidly in isolating, sequencing, and cloning the virus, and developing diagnostic kits, within a matter of weeks. However, major knowledge gaps remain about the dynamic interaction between the human immune system and the SARS-CoV-2. In particular, several fundamental questions regarding its pathogenesis, and the mechanisms of protective immunity that need to be induced by vaccination, remain unanswered. Learning how the immune system senses SARS-CoV-2 infection and orchestrates protective immunity is critical for designing effective vaccines and therapeutics. Our previous work using systems biology, multi-omics approaches to analyze immune responses to vaccination in humans has delineated molecular signatures of innate immunity to vaccination and infection and have provided rich mechanistic insights into the immune response1-7. In this proposal, we propose a site-specific study to analyze samples from the IMPACC sub-study performed at Emory. We will use an integrated multi-omics approach (single cell transcriptomics, metabolomics, single cell epigenomics) to study innate immunity to COVID- 19 infection in humans. We will obtain PBMCs and tracheal aspirate samples from the IMPACC sub-study that will be conducted at Emory. We will address the following questions: What are the molecular and cellular signatures of the immune response to COVID-19 infection in the blood and tracheal aspirates of infected subjects? Does COVID-19 infection exert an epigenetic imprint of innate immunity? What is the molecular landscape and function of myeloid cell subsets and airway epithelial cells in the healthy lung, and following COVID-19 infection? These questions will be addressed in the following specific aims: 1) Determine the single cell transcriptional and epigenetic landscape of the immune response to COVID-19 infection in blood and tracheal aspirates, and 2) Determine the molecular identity and functions of myeloid cell subsets and epithelial cells in human lung and their response to COVID-19 infection. These studies will provide significant insight into the human immune response to COVID-19 infection that can be leveraged for designing vaccines and therapeutics to prevent or treat the infection.", "keywords": [ "2019-nCoV", "ATAC-seq", "Address", "Aspirate substance", "Award", "Blood", "COVID-19", "Cell Culture Techniques", "Cells", "Cloning", "Competence", "Diagnostic", "Disease", "Donor person", "Epigenetic Process", "Epithelial Cells", "Epitopes", "Genetic Transcription", "Grant", "Heterogeneity", "Hospitals", "Human", "Immune", "Immune response", "Immune system", "Immunity", "Immunology", "Infection", "Innate Immune Response", "Knowledge", "Learning", "Lung", "Lung Transplantation", "Metabolic", "Molecular", "Molecular Profiling", "Myelogenous", "Myeloid Cells", "Natural Immunity", "Parents", "Pathogenesis", "Pathogenicity", "Peripheral Blood Mononuclear Cell", "Sampling", "Science", "Site", "Stimulus", "Structure of parenchyma of lung", "System", "Systems Biology", "Therapeutic", "Vaccination", "Vaccine Design", "Vaccines", "Virus", "Work", "airway epithelium", "biological systems", "coronavirus disease", "design", "epigenomics", "global health", "imprint", "indexing", "insight", "macrophage", "metabolomics", "monocyte", "multiple omics", "novel", "pandemic disease", "prevent", "programs", "response", "single-cell RNA sequencing", "transcriptome", "transcriptomics", "transplant centers" ], "approved": true } }, { "type": "Grant", "id": "7428", "attributes": { "award_id": "3UM1AI148576-01S1", "title": "Vaccine and Treatment Evaluation Units", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22843, "first_name": "RANJODH SUNNY", "last_name": "Gill", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-03-12", "end_date": "2021-11-30", "award_amount": 5485363, "principal_investigator": { "id": 23222, "first_name": "EVAN J", "last_name": "ANDERSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23171, "first_name": "Nadine Georges", "last_name": "Rouphael", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23223, "first_name": "Carlos", "last_name": "del Rio", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The currently NIAID-funded Vaccine and Treatment Evaluation Unit (VTEU) based at Emory University is ideally positioned to implement the mission of the Infectious Diseases Clinical Research Consortium (IDCRC). The Emory VTEU is supported by Emory's rich scientific milieu with numerous synergistic grants and various thematic research centers covering all IDCRC scientific priority areas. The Emory VTEU infrastructure relies on two clinical research sites with a total of 16,000 square feet of clinical, laboratory, and pharmacy space and 83 faculty members and staff. Over the past decade as a funded VTEU, we have conducted 51 VTEU protocols, served as lead on 25 trials, performed endpoint assays for 17 studies, and published 22 high impact papers. We have enrolled ~3,000 participants, 55% are female and 37% from diverse racial and ethnic backgrounds with a retention rate of ~93%. With its flexible infrastructure, the Emory VTEU demonstrated surge capacity to contribute to pandemic influenza, Zika, Ebola, and biodefense efforts by prioritizing resources in funds and staffing. The Emory VTEU will build on the current surge capacity by strengthening our partnership with the Georgia Clinical and Translational Science Alliance and collaborating with well-established Emory international partners on a protocol-specific basis. Additionally, to date, our VTEU has trained 28 fellows and junior faculty. We will build on our significant record of accomplishment and advance the IDCRC mission by implementing the following specific aims: 1. Engage a broad range of Emory scientists with expertise in established and newly emerging infectious diseases in the core science of the IDCRC including concept generation and protocol development. 2. Leverage our access to a unique and diverse population and state-of-the-art research infrastructure to implement all components of the IDCRC science, including study conduct, data quality control and assurance procedures, data management, and good clinical, laboratory, and pharmacy practices. 3. Optimize our operational flexibility to further enhance our ability to provide surge capacity to address emerging infectious diseases and pandemic response. 4. Expand our mentoring capacity and enhance career development opportunities for early stage investigators in the areas of vaccinology, infectious diseases diagnostics, therapeutics, and prevention.", "keywords": [ "Acquired Immunodeficiency Syndrome", "Address", "Adult", "Anthrax disease", "Antibiotic Resistance", "Antimicrobial Resistance", "Area", "Biological Response Modifier Therapy", "Categories", "Centers for Disease Control and Prevention (U.S.)", "Childhood", "Clinical", "Clinical Protocols", "Clinical Research", "Clinical Sciences", "Clinical Trials", "Clinical Trials Unit", "Communicable Diseases", "Communities", "Complex", "Consent", "Databases", "Dedications", "Devices", "Diagnostic", "Disease Outcome", "Drug Kinetics", "Ebola", "Elderly", "Emerging Communicable Diseases", "End Point Assay", "Enrollment", "Ensure", "Environment", "Epidemic", "Ethnic Origin", "Evaluation", "Faculty", "Female", "Funding", "Generations", "Grant", "HIV", "Healthcare Systems", "Human", "Immunologic Tests", "Immunologics", "Immunology", "Individual", "Infection", "Influenza", "Influenza A Virus H5N1 Subtype", "Influenza A Virus H7N9 Subtype", "Influenza A virus", "Infrastructure", "Institutes", "Institution", "International", "Laboratories", "Laboratory Research", "Lead", "Leadership", "Malaria", "Mentors", "Mission", "Modeling", "National Institute of Allergy and Infectious Disease", "Outpatients", "Paper", "Participant", "Patients", "Pharmacy facility", "Phase", "Population Heterogeneity", "Positioning Attribute", "Prevention", "Procedures", "Prognostic Marker", "Protocols documentation", "Publications", "Publishing", "Quality Control", "Race", "Research", "Research Infrastructure", "Research Personnel", "Research Training", "Resources", "Risk", "Route", "Science", "Scientist", "Sexually Transmitted Diseases", "Site", "Smallpox", "Specimen Handling", "Structure", "Systems Biology", "Talents", "Therapeutic", "Training", "Training and Education", "Translational Research", "Tuberculosis", "Tularemia", "Universities", "Vaccines", "ZIKA", "base", "biodefense", "career development", "chikungunya", "clinical data warehouse", "clinical research site", "data management", "data quality", "design", "enteric pathogen", "flexibility", "global health", "improved outcome", "member", "neglected tropical diseases", "next generation", "novel", "pandemic disease", "pandemic influenza", "pathogen", "predictive marker", "pregnant", "prevent", "programs", "protocol development", "quality assurance", "racial and ethnic", "racial diversity", "recruit", "respiratory", "response", "retention rate", "square foot", "study po" ], "approved": true } }, { "type": "Grant", "id": "8220", "attributes": { "award_id": "3UM1AI148576-02S2", "title": "Emory Vaccine and Treatment Evaluation Unit - KidCOVE", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24053, "first_name": "OLIVIA CAHN", "last_name": "Sparer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-04-26", "end_date": "2023-02-28", "award_amount": 1475091, "principal_investigator": { "id": 23222, "first_name": "EVAN J", "last_name": "ANDERSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23171, "first_name": "Nadine Georges", "last_name": "Rouphael", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23223, "first_name": "Carlos", "last_name": "del Rio", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "Narrative The Emory VTEU will participate and enroll children into “A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age (KidCOVE)”. 1", "keywords": [ "12 year old", "Age", "COVID-19 pandemic", "COVID-19 vaccine", "Child", "Childhood", "Clinical Trials", "Dose", "Effectiveness", "Enrollment", "Evaluation", "Funding", "Moderna COVID-19 vaccine", "Phase", "Placebos", "Randomized", "Safety", "Vaccines", "blind", "fight against", "open label" ], "approved": true } }, { "type": "Grant", "id": "8516", "attributes": { "award_id": "3UM1AI148576-02S4", "title": "Vaccine and Treatment Evaluation Units - DMID 21-0012", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24053, "first_name": "OLIVIA CAHN", "last_name": "Sparer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-07-08", "end_date": "2025-11-30", "award_amount": 1169796, "principal_investigator": { "id": 23222, "first_name": "EVAN J", "last_name": "ANDERSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23171, "first_name": "Nadine Georges", "last_name": "Rouphael", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "Summary/Abstract The Emory VTEU will participate in DMID 21-0012, A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) after Receipt of EUA Vaccines. Knowledge of the safety, tolerability, and immunogenicity of SARS-CoV-2 delayed homologous and heterologous boost vaccine incorporating a similar or variant spike administered following EUA dosing regimens might induce immunity to variant circulating strains and improve upon breadth and durability of protection. Utilizing the EUA-dosed COVID-19 vaccines available (currently mRNA-1273, mRNA- BNT162b2, and AD26.COV2.S), we propose to evaluate innate, cellular, and humoral immune responses elicited from multiple prime boost combinations, utilizing the mRNA with homologous spike protein as a boost while seeking to avoid duplicating trial designs currently in planning stages or in process. This phase 1/2 study will evaluate the safety, tolerability, and immunogenicity of delayed homologous or heterologous boost SARS-CoV-2 vaccines in two cohorts of healthy adult participants, one of which has received EUA vaccinations and one of which is vaccine-naïve. We will follow these participants for 12 months following receipt of the delayed boost. In addition to screening and vaccination visits, study visits will occur at 2 weeks, 1, 3, 6, and 12 months post-vaccination with blood collection for immunogenicity assessments. Solicited adverse events (AEs) will be collected using a memory aid and recorded on the appropriate DCF from the time of each vaccination through 7 days post each vaccination. Unsolicited AEs will be collected through 28 days post each vaccination. And after 28 days post last vaccination through the end of study, only SAEs, Protocol Specified adverse events of special interest (AESIs), medically attended adverse events (MAAEs), and new-onset medical conditions (NOCMCs) will be reported as AEs. The study will be conducted across the two Emory VTEU sites: Emory Children’s Center (ECC-VRC) and Hope Clinic. Recruitment and enrollment will occur at both sites. The Emory VTEU has proven essential in the fight against the pandemic. This supplement will allow for further investigations into vaccines trials studying vaccine dosing boosts. 1", "keywords": [ "2019-nCoV", "Adult", "Adverse event", "Blood", "COVID-19 vaccine", "Child", "Clinic", "Collection", "Dose", "Enrollment", "Evaluation", "Immune response", "Immunity", "Investigation", "Knowledge", "Medical", "Memory", "Messenger RNA", "Moderna COVID-19 vaccine", "Participant", "Pfizer-BioNTech COVID-19 vaccine", "Phase", "Process", "Proteins", "Protocols documentation", "Regimen", "Reporting", "Safety", "Schedule", "Site", "Special Event", "Specific qualifier value", "Time", "Vaccination", "Vaccines", "Variant", "Visit", "cohort", "fight against", "immunogenicity", "improved", "interest", "pandemic disease", "recruit", "screening", "trial design", "vaccine access", "vaccine trial" ], "approved": true } }, { "type": "Grant", "id": "7376", "attributes": { "award_id": "3U19AI090023-11S1", "title": "System Biological Analyses of Innate and Adaptive Responses to Vaccination", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6484, "first_name": "Gang", "last_name": "Dong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-07-13", "end_date": "2022-06-30", "award_amount": 7425306, "principal_investigator": { "id": 6019, "first_name": "Rafi", "last_name": "Ahmed", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 7241, "first_name": "BALI", "last_name": "PULENDRAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 23170, "first_name": "Shuzhao", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23171, "first_name": "Nadine Georges", "last_name": "Rouphael", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23172, "first_name": "Shankar", "last_name": "Subramaniam", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23173, "first_name": "Nir", "last_name": "Yosef", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23174, "first_name": "Tianwei", "last_name": "Yu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) pandemic poses a major global health challenge. Coronavirus disease (COVID-19) is caused by SARS- CoV-2 and represents the causative agent of a potentially fatal disease. Science has moved very rapidly in isolating, sequencing, and cloning the virus, and developing diagnostic kits, within a matter of weeks. However, major knowledge gaps remain about the dynamic interaction between the human immune system and the SARS-CoV-2. In particular, several fundamental questions regarding its pathogenesis, and the mechanisms of protective immunity that need to be induced by vaccination, remain unanswered. Learning how the immune system senses SARS-CoV-2 infection and orchestrates protective immunity is critical for designing effective vaccines and therapeutics. Our previous work using systems biology, multi-omics approaches to analyze immune responses to vaccination in humans has delineated molecular signatures of innate immunity to vaccination and infection and have provided rich mechanistic insights into the immune response1-7. In this proposal, we propose a site-specific study to analyze samples from the IMPACC sub-study performed at Emory. We will use an integrated multi-omics approach (single cell transcriptomics, metabolomics, single cell epigenomics) to study innate immunity to COVID- 19 infection in humans. We will obtain PBMCs and tracheal aspirate samples from the IMPACC sub-study that will be conducted at Emory. We will address the following questions: What are the molecular and cellular signatures of the immune response to COVID-19 infection in the blood and tracheal aspirates of infected subjects? Does COVID-19 infection exert an epigenetic imprint of innate immunity? What is the molecular landscape and function of myeloid cell subsets and airway epithelial cells in the healthy lung, and following COVID-19 infection? These questions will be addressed in the following specific aims: 1) Determine the single cell transcriptional and epigenetic landscape of the immune response to COVID-19 infection in blood and tracheal aspirates, and 2) Determine the molecular identity and functions of myeloid cell subsets and epithelial cells in human lung and their response to COVID-19 infection. These studies will provide significant insight into the human immune response to COVID-19 infection that can be leveraged for designing vaccines and therapeutics to prevent or treat the infection.", "keywords": [ "2019-nCoV", "ATAC-seq", "Address", "Aspirate substance", "Award", "Blood", "COVID-19", "Cell Culture Techniques", "Cells", "Cloning", "Competence", "Diagnostic", "Disease", "Donor person", "Epigenetic Process", "Epithelial Cells", "Epitopes", "Genetic Transcription", "Grant", "Heterogeneity", "Hospitals", "Human", "Immune", "Immune response", "Immune system", "Immunity", "Immunology", "Infection", "Innate Immune Response", "Knowledge", "Learning", "Lung", "Lung Transplantation", "Metabolic", "Molecular", "Molecular Profiling", "Myelogenous", "Myeloid Cells", "Natural Immunity", "Parents", "Pathogenesis", "Pathogenicity", "Peripheral Blood Mononuclear Cell", "Sampling", "Science", "Site", "Stimulus", "Structure of parenchyma of lung", "System", "Systems Biology", "Therapeutic", "Vaccination", "Vaccine Design", "Vaccines", "Virus", "Work", "airway epithelium", "biological systems", "coronavirus disease", "design", "epigenomics", "global health", "imprint", "indexing", "insight", "macrophage", "metabolomics", "monocyte", "multiple omics", "novel", "pandemic disease", "prevent", "programs", "response", "single-cell RNA sequencing", "transcriptome", "transcriptomics", "transplant centers" ], "approved": true } }, { "type": "Grant", "id": "7376", "attributes": { "award_id": "3U19AI090023-11S1", "title": "System Biological Analyses of Innate and Adaptive Responses to Vaccination", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6484, "first_name": "Gang", "last_name": "Dong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-07-13", "end_date": "2022-06-30", "award_amount": 7425306, "principal_investigator": { "id": 6019, "first_name": "Rafi", "last_name": "Ahmed", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 7241, "first_name": "BALI", "last_name": "PULENDRAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 23170, "first_name": "Shuzhao", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23171, "first_name": "Nadine Georges", "last_name": "Rouphael", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23172, "first_name": "Shankar", "last_name": "Subramaniam", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23173, "first_name": "Nir", "last_name": "Yosef", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23174, "first_name": "Tianwei", "last_name": "Yu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) pandemic poses a major global health challenge. Coronavirus disease (COVID-19) is caused by SARS- CoV-2 and represents the causative agent of a potentially fatal disease. Science has moved very rapidly in isolating, sequencing, and cloning the virus, and developing diagnostic kits, within a matter of weeks. However, major knowledge gaps remain about the dynamic interaction between the human immune system and the SARS-CoV-2. In particular, several fundamental questions regarding its pathogenesis, and the mechanisms of protective immunity that need to be induced by vaccination, remain unanswered. Learning how the immune system senses SARS-CoV-2 infection and orchestrates protective immunity is critical for designing effective vaccines and therapeutics. Our previous work using systems biology, multi-omics approaches to analyze immune responses to vaccination in humans has delineated molecular signatures of innate immunity to vaccination and infection and have provided rich mechanistic insights into the immune response1-7. In this proposal, we propose a site-specific study to analyze samples from the IMPACC sub-study performed at Emory. We will use an integrated multi-omics approach (single cell transcriptomics, metabolomics, single cell epigenomics) to study innate immunity to COVID- 19 infection in humans. We will obtain PBMCs and tracheal aspirate samples from the IMPACC sub-study that will be conducted at Emory. We will address the following questions: What are the molecular and cellular signatures of the immune response to COVID-19 infection in the blood and tracheal aspirates of infected subjects? Does COVID-19 infection exert an epigenetic imprint of innate immunity? What is the molecular landscape and function of myeloid cell subsets and airway epithelial cells in the healthy lung, and following COVID-19 infection? These questions will be addressed in the following specific aims: 1) Determine the single cell transcriptional and epigenetic landscape of the immune response to COVID-19 infection in blood and tracheal aspirates, and 2) Determine the molecular identity and functions of myeloid cell subsets and epithelial cells in human lung and their response to COVID-19 infection. These studies will provide significant insight into the human immune response to COVID-19 infection that can be leveraged for designing vaccines and therapeutics to prevent or treat the infection.", "keywords": [ "2019-nCoV", "ATAC-seq", "Address", "Aspirate substance", "Award", "Blood", "COVID-19", "Cell Culture Techniques", "Cells", "Cloning", "Competence", "Diagnostic", "Disease", "Donor person", "Epigenetic Process", "Epithelial Cells", "Epitopes", "Genetic Transcription", "Grant", "Heterogeneity", "Hospitals", "Human", "Immune", "Immune response", "Immune system", "Immunity", "Immunology", "Infection", "Innate Immune Response", "Knowledge", "Learning", "Lung", "Lung Transplantation", "Metabolic", "Molecular", "Molecular Profiling", "Myelogenous", "Myeloid Cells", "Natural Immunity", "Parents", "Pathogenesis", "Pathogenicity", "Peripheral Blood Mononuclear Cell", "Sampling", "Science", "Site", "Stimulus", "Structure of parenchyma of lung", "System", "Systems Biology", "Therapeutic", "Vaccination", "Vaccine Design", "Vaccines", "Virus", "Work", "airway epithelium", "biological systems", "coronavirus disease", "design", "epigenomics", "global health", "imprint", "indexing", "insight", "macrophage", "metabolomics", "monocyte", "multiple omics", "novel", "pandemic disease", "prevent", "programs", "response", "single-cell RNA sequencing", "transcriptome", "transcriptomics", "transplant centers" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1392, "count": 13920 } } }